The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
80 jobs Number of planned job losses
Announcement Date
14 January 2011
Employment effect (start)
14 January 2011
Foreseen end date
Description
On 14 January 2011, the biopharmaceutical company Innogenetics, located in Gent, announced the loss of 80 jobs, one- third of the current workforce. The dismissals procedure has already been launched. The job losses are announced six month after the buyout of the company by the Japanese group Fujirebio. The job reductions are blamed on the need to move away from research and development toward sales and distribution.
Sources
14 January 2011: L'Echo
Citation
Eurofound (2011), Innogenetics, Internal restructuring in Belgium, factsheet number 71465, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/71465.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
